Virtus ETF Advisers’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-7,494
| Closed | -$79K | – | 467 |
|
|
2023
Q1 | $79K | Buy |
7,494
+133
| +2% | +$4.02K | 0.04% | 386 |
|
|
2022
Q4 | $250K | Buy |
7,361
+2,560
| +53% | +$124K | 0.13% | 304 |
|
|
2022
Q3 | $230K | Buy |
4,801
+70
| +1% | +$4.17K | 0.09% | 303 |
|
|
2022
Q2 | $270K | Buy |
4,731
+2,775
| +142% | +$175K | 0.1% | 280 |
|
|
2022
Q1 | $158K | Hold |
1,956
| – | – | 0.07% | 219 |
|
|
2021
Q4 | $396K | Buy |
1,956
+232
| +13% | +$50.3K | 0.15% | 155 |
|
|
2021
Q3 | $465K | Sell |
1,724
-159
| -8% | -$38.2K | 0.2% | 150 |
|
|
2021
Q2 | $485K | Sell |
1,883
-482
| -20% | -$133K | 0.2% | 158 |
|
|
2021
Q1 | $710K | Buy |
2,365
+65
| +3% | +$20.2K | 0.3% | 106 |
|
|
2020
Q4 | $587K | Buy |
2,300
+398
| +21% | +$103K | 0.24% | 121 |
|
|
2020
Q3 | $473K | Buy |
1,902
+161
| +9% | +$50.6K | 0.25% | 144 |
|
|
2020
Q2 | $605K | Sell |
1,741
-103
| -6% | -$32.1K | 0.29% | 116 |
|
|
2020
Q1 | $494K | Sell |
1,844
-156
| -8% | -$48.3K | 0.2% | 171 |
|
|
2019
Q4 | $648K | Buy |
2,000
+617
| +45% | +$179K | 0.11% | 170 |
|
|
2019
Q3 | $378K | Sell |
1,383
-248
| -15% | -$91K | 0.08% | 190 |
|
|
2019
Q2 | $870K | Buy |
+1,631
| New | +$818K | 0.18% | 163 |
|
|
2019
Q1 | – | Sell |
-1,106
| Closed | -$545K | – | 222 |
|
|
2018
Q4 | $545K | Buy |
1,106
+181
| +20% | +$109K | 0.09% | 72 |
|
|
2018
Q3 | $846K | Buy |
925
+62
| +7% | +$52.9K | 0.09% | 62 |
|
|
2018
Q2 | $632K | Sell |
863
-138
| -14% | -$159K | 0.56% | 126 |
|
|
2018
Q1 | $1.59M | Sell |
1,001
-125
| -11% | -$161K | 1.38% | 5 |
|
|
2017
Q4 | $1.01M | Sell |
1,126
-2,616
| -70% | -$1.55M | 1.27% | 17 |
|
|
2017
Q3 | $1.35M | Hold |
3,742
| – | – | 0.18% | 41 |
|
|
2017
Q2 | $1.1M | Sell |
3,742
-1,925
| -34% | -$556K | 0.16% | 52 |
|
|
2017
Q1 | $2M | Buy |
5,667
+545
| +11% | +$123K | 0.36% | 36 |
|
|
2016
Q4 | $943K | Buy |
5,122
+2,364
| +86% | +$481K | 0.28% | 61 |
|
|
2016
Q3 | $711K | Buy |
2,758
+348
| +14% | +$89.6K | 0.34% | 50 |
|
|
2016
Q2 | $514K | Sell |
2,410
-141
| -6% | -$31.5K | 0.38% | 55 |
|
|
2016
Q1 | $526K | Hold |
2,551
| – | – | 0.72% | 36 |
|
|
2015
Q4 | $645K | Buy |
+2,551
| New | +$525K | 1.77% | 14 |
|
Other funds holding NKTR
DTC
MAM
SCM
Virtus ETF Advisers's NKTR Position: Q2 2023 in Review
Virtus ETF Advisers sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 7,494 shares — an estimated $79K sold.
Virtus ETF Advisers first reported a position in NKTR in Q4 2015 and held it in 29 quarters. The position peaked at $2M in Q1 2017. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.
- Virtus ETF Advisers reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
- Virtus ETF Advisers sold 7,494 Nektar Therapeutics shares in Q2 2023, an estimated $79K.
- Virtus ETF Advisers first reported a position in Nektar Therapeutics in Q4 2015 and held it in 29 quarters.
- Virtus ETF Advisers's Nektar Therapeutics position peaked at $2M in Q1 2017.
- 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.
Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.